Role of the IL-23-T-bet/GATA3 Axis for the Pathogenesis of Ulcerative Colitis.
Adolescent
Adult
Aged
Aged, 80 and over
Cluster Analysis
Colitis, Ulcerative
/ diagnosis
Colon
/ immunology
Cytokines
/ immunology
Female
GATA3 Transcription Factor
/ immunology
Humans
Interleukin-23
/ immunology
Intestinal Mucosa
/ immunology
Male
Middle Aged
Real-Time Polymerase Chain Reaction
Retrospective Studies
T-Box Domain Proteins
/ immunology
Th1 Cells
/ immunology
Th17 Cells
/ immunology
Th2 Cells
/ immunology
Young Adult
GATA3
IL-23
T-bet
UC
Journal
Inflammation
ISSN: 1573-2576
Titre abrégé: Inflammation
Pays: United States
ID NLM: 7600105
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
18
08
2020
accepted:
02
10
2020
pubmed:
12
10
2020
medline:
10
11
2021
entrez:
11
10
2020
Statut:
ppublish
Résumé
Ulcerative colitis (UC) has been considered a Th2- and Th17-related disease. However, anti-IL-12/23 p40 antibody, which blocks Th1 and Th17 cell induction and maintenance, has shown efficacy in treating UC, suggesting that UC might not be a prototypical Th2 and Th17 cell-mediated autoimmune disease. To verify how the immune responses in UC patients interact with each other, we analyzed the cytokine expression and transcription factors involved in the Th1, Th2, and Th17 responses. The mucosal expression of 19 cytokines and transcription factors related to Th1, Th2, and Th17 cells, as well as Tregs, were measured by quantitative polymerase chain reaction using endoscopic biopsy specimens from inflamed colons of UC patients. A correlation analysis between the cytokines and transcription factors was conducted. The characteristic cytokine profile in UC patients has two immune response clusters: Th17-related responses and Th1-/Th2-related responses. IL-23 showed a weaker association with Th17 cell-related cytokines and transcription factor RORC and a much stronger correlation with T-bet and GATA3. In the high-IL-23-expression group, the rate of chronic continuous type was higher and the remission rate lower than in the low-IL-23-expression group. IL-23 may be a very important cytokine for evaluating the UC disease condition, as the expression of IL-23 is associated with certain clinical characteristics of UC patients. A unique association between IL-23 and T-bet/GATA3 might play a key role in the pathogenesis of UC.
Identifiants
pubmed: 33040251
doi: 10.1007/s10753-020-01358-y
pii: 10.1007/s10753-020-01358-y
doi:
Substances chimiques
Cytokines
0
GATA3 Transcription Factor
0
GATA3 protein, human
0
Interleukin-23
0
T-Box Domain Proteins
0
T-box transcription factor TBX21
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
592-603Subventions
Organisme : KAKENHI
ID : 20K08389
Références
Morrison, G., B. Headon, and P. Gibson. 2009. Update in inflammatory bowel disease. Australian Family Physician. 38: 956–961.
pubmed: 20369146
Geremia, A., P. Biancheri, P. Allan, G.R. Corazza, and A. di Sabatino. 2014. Innate and adaptive immunity in inflammatory bowel disease. Autoimmunity Reviews. 13: 3–10.
doi: 10.1016/j.autrev.2013.06.004
Xavier, R.J., and D.K. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 448: 427–434.
doi: 10.1038/nature06005
Rosen, M.J., R. Karns, J.E. Vallance, R. Bezold, A. Waddell, M.H. Collins, Y. Haberman, P. Minar, R.N. Baldassano, J.S. Hyams, S.S. Baker, R. Kellermayer, J.D. Noe, A.M. Griffiths, J.R. Rosh, W.V. Crandall, M.B. Heyman, D.R. Mack, M.D. Kappelman, J. Markowitz, D.E. Moulton, N.S. Leleiko, T.D. Walters, S. Kugathasan, K.T. Wilson, S.P. Hogan, and L.A. Denson. 2017. Mucosal expression of type 2 and type 17 immune response genes distinguishes ulcerative colitis from colon-only Crohn’s disease in treatment-naive pediatric patients. Gastroenterology. 152: 1345–1357.
doi: 10.1053/j.gastro.2017.01.016
Hirahara, K., and T. Nakayama. 2016. CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. International Immunology 28: 163–171.
doi: 10.1093/intimm/dxw006
Imam, T., S. Park, M.H. Kaplan, and M.R. Olson. 2018. Effector T helper cell subsets in inflammatory bowel diseases. Frontiers in Immunology. 9: 1212.
doi: 10.3389/fimmu.2018.01212
Iboshi, Y., K. Nakamura, E. Ihara, T. Iwasa, H. Akiho, N. Harada, M. Nakamuta, and R. Takayanagi. 2014. Multigene analysis unveils distinctive expression pro files of helper T-cell – related genes in the intestinal mucosa that discriminate between ulcerative colitis and Crohn’s disease. Inflammatory Bowel Diseases 20: 967–977.
pubmed: 24739631
Feagan, B.G., W.J. Sandborn, C. Gasink, D. Jacobstein, Y. Lang, J.R. Friedman, M.A. Blank, J. Johanns, L.L. Gao, Y. Miao, O.J. Adedokun, B.E. Sands, S.B. Hanauer, S. Vermeire, S. Targan, S. Ghosh, W.J. de Villiers, J.F. Colombel, Z. Tulassay, U. Seidler, B.A. Salzberg, P. Desreumaux, S.D. Lee, Loftus EV Jr, L.A. Dieleman, S. Katz, P. Rutgeerts, and UNITI–IM-UNITI Study Group. 2016. Ustekinumab as induction and maintenance therapy for Crohn’s disease. New England Journal of Medicine. 375: 1946–1960.
doi: 10.1056/NEJMoa1602773
Sands, B.E., W.J. Sandborn, R. Panaccione, C.D. O'Brien, H. Zhang, J. Johanns, O.J. Adedokun, K. Li, L. Peyrin-Biroulet, G. van Assche, S. Danese, S. Targan, M.T. Abreu, T. Hisamatsu, P. Szapary, C. Marano, and UNIFI Study Group. 2019. Ustekinumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine. 381: 1201–1214.
doi: 10.1056/NEJMoa1900750
Reinisch, W., J. Panés, S. Khurana, G. Toth, F. Hua, G.M. Comer, M. Hinz, K. Page, M. O'Toole, T.M.D. Moorehead, H. Zhu, Y.H. Sun, and F. Cataldi. 2015. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 64: 894–900.
doi: 10.1136/gutjnl-2014-308337
Danese, S., J. Rudziński, W. Brandt, J.L. Dupas, L. Peyrin-Biroulet, Y. Bouhnik, D. Kleczkowski, P. Uebel, M. Lukas, M. Knutsson, F. Erlandsson, M.B. Hansen, and S. Keshav. 2015. Tralokinumab for moderate-to-severe UC: A randomised, double-blind, placebo-controlled, phase IIa study. Gut. 64: 243–249.
doi: 10.1136/gutjnl-2014-308004
Ehrlich, D., N. Jamaluddin, J. Pisegna, and D. Padua. 2018. A challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis. Case Reports in Gastrointestinal Medicine. 2018: 1–4.
doi: 10.1155/2018/9679287
Orrell, K.A., M. Murphrey, R.C. Kelm, H.H. Lee, D.R. Pease, A.E. Laumann, D.P. West, and B. Nardone. 2018. Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: postmarketing analysis from the RADAR (“Research on Adverse Drug events and Reports”) program. Journal of the American Academy of Dermatology. 79: 777–778.
doi: 10.1016/j.jaad.2018.06.024
Lozano, M.J.F., R.S. Giménez, and M.C. Fernández. 2018. Emergence of inflammatory bowel disease during treatment with secukinumab. Journal of Crohn’s and Colitis. 12: 1131–1133.
Ogino, H., K. Nakamura, E. Ihara, H. Akiho, and R. Takayanagi. 2011. CD4+CD25+ regulatory T cells suppress Th17-responses in an experimental colitis model. Digestive Diseases and Sciences. 56: 376–386.
doi: 10.1007/s10620-010-1286-2
Fukaura, K., Y. Iboshi, H. Ogino, E. Ihara, K. Nakamura, Y. Nishihara, K. Nishioka, T. Chinen, T. Iwasa, A. Aso, A. Goto, K. Haraguchi, H. Akiho, N. Harada, and Y. Ogawa. 2019. Mucosal profiles of immune molecules related to T helper and regulatory T cells predict future relapse in patients with quiescent ulcerative colitis. Inflammatory Bowel Diseases. 25: 1019–1027.
doi: 10.1093/ibd/izy395
Wallner, F.K., M. Hultqvist Hopkins, T. Lindvall, P. Olofsson, and A. Tilevik. 2017. Cytokine correlation analysis based on drug perturbation. Cytokine 90: 73–79.
doi: 10.1016/j.cyto.2016.10.015
Allocca, M., F. Furfaro, G. Fiorino, et al. 2018. Can IL-23 be a good target for ulcerative colitis? Best Practice and Research: Clinical Gastroenterology. 32–33: 95–102.
doi: 10.1016/j.bpg.2018.05.016
Ueno, A., L. Jeffery, T. Kobayashi, T. Hibi, S. Ghosh, and H. Jijon. 2018. Th17 plasticity and its relevance to inflammatory bowel disease. Journal of Autoimmunity. 87: 38–49.
doi: 10.1016/j.jaut.2017.12.004
Li, J., A. Ueno, M. Iacucci, M. Fort Gasia, H.B. Jijon, R. Panaccione, G.G. Kaplan, P.L. Beck, J. Luider, H.W. Barkema, J. Qian, X. Gui, and S. Ghosh. 2017. Crossover subsets of CD4+T lymphocytes in the intestinal lamina propria of patients with Crohn’s disease and ulcerative colitis. Digestive Diseases and Sciences. 62: 2357–2368.
doi: 10.1007/s10620-017-4596-9
Harrison, O.J., J.L. Linehan, H.-Y. Shih, et al. 2019. Commensal-specific T cell plasticity promotes rapid tissue adaptation to injury. Science. 363: 1–27.
doi: 10.1126/science.363.6433.1358
Hirota, K., J.H. Duarte, M. Veldhoen, E. Hornsby, Y. Li, D.J. Cua, H. Ahlfors, C. Wilhelm, M. Tolaini, U. Menzel, A. Garefalaki, A.J. Potocnik, and B. Stockinger. 2011. Fate mapping of IL-17-producing T cells in inflammatory responses. Nature Immunology 12: 255–263.
doi: 10.1038/ni.1993
Globig, A.M., N. Hennecke, B. Martin, M. Seidl, G. Ruf, P. Hasselblatt, R. Thimme, and B. Bengsch. 2014. Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-γ+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease. Inflammatory Bowel Diseases. 20: 2321–2329.
doi: 10.1097/MIB.0000000000000210
Kobayashi, T., S. Okamoto, T. Hisamatsu, N. Kamada, H. Chinen, R. Saito, M.T. Kitazume, A. Nakazawa, A. Sugita, K. Koganei, K. Isobe, and T. Hibi. 2008. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut. 57: 1682–1689.
doi: 10.1136/gut.2007.135053
Wakashin, H., K. Hirose, Y. Maezawa, S.I. Kagami, A. Suto, N. Watanabe, Y. Saito, M. Hatano, T. Tokuhisa, Y. Iwakura, P. Puccetti, I. Iwamoto, and H. Nakajima. 2008. IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. American Journal of Respiratory and Critical Care Medicine. 178: 1023–1032.
doi: 10.1164/rccm.200801-086OC
Peng, Juan, Xuexian O. Yang, and Seon Hee Chang. 2010. Jiong Yang and CD. IL-23 signaling enhances Th2 polarization and regulates allergic airway inflammation. Cell Research 20: 62–71.
doi: 10.1038/cr.2009.128
Gieseck, R.L., M.S. Wilson, and T.A. Wynn. 2018. Type 2 immunity in tissue repair and fibrosis. Nature Reviews Immunology. 18: 62–76.
doi: 10.1038/nri.2017.90
Oeser, K., C. Schwartz, and D. Voehringer. 2015. Conditional IL-4/IL-13-deficient mice reveal a critical role of innate immune cells for protective immunity against gastrointestinal helminths. Mucosal Immunology. 8: 672–682.
doi: 10.1038/mi.2014.101
O'Connor, W., Jr., M. Kamanaka, C.J. Booth, et al. 2009. A protective function for interleukin 17A in T cell–mediated intestinal inflammation. Nature Immunology 10: 603–609.
doi: 10.1038/ni.1736
Butera, A., M. di Paola, F. Vitali, D. de Nitto, F. Covotta, F. Borrini, R. Pica, C. de Filippo, D. Cavalieri, A. Giuliani, A. Pronio, and M. Boirivant. 2020. IL-13 mRNA tissue content identifies two subsets of adult ulcerative colitis patients with different clinical and mucosa-associated microbiota profiles. Journal of Crohn’s and Colitis. 14: 369–380.
doi: 10.1093/ecco-jcc/jjz154